The sensitivity of the method of testing is especially important for the use of some plasma products, rather than whole blood or packed cells. The products manufactured for treating the haemophilias, factor VIII and IX concentrates, are prepared from up to 5000 plasma donations, and the risk of contamination of these large pools is high. As a result the group has recommended that only the most sensitive techniques should be employed for all plasma donations sent for fractionation. The major difficulty in attempts to eliminate post-transfusion hepatitis, however, remains the absence of markers for the non-A, non-B viruses. So, though increased sensitivity of donor screening (together with the prospects3 for immunisation of at-risk groups) will virtually, but not completely, remove the threat of HBsAg-positive disease, the diagnosis of non-A, non-B hepatitis remains non-specific, and its true incidence remains unknown. Experience with haemophiliacs suggests that the non-A, non-B infection is often subicteric, presenting as a short incubation influenza-like 
